Allogeneic CD19-targeting T cells for treatment-refractory systemic lupus erythematosus: a phase 1 trial
Nat Med. 2025 Aug 27. doi: 10.1038/s41591-025-03899-x. Online ahead of print. ABSTRACT Commercial autologous anti-CD19 chimeric antigen receptor-T cell therapies […]
